ERBB2 and osteosarcoma: After the failure of trastuzumab, the development of HER2-targeted therapy for osteosarcoma stopped, although new HER2-targeted drugs (antibody, antibody-drug conjugates or TKIs) were investigated and approved for other malignancies.